Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Defined Small Molecules Produced by Himalayan Medicinal Plants Display Immunomodulatory Properties.

Wangchuk P, Apte SH, Smout MJ, Groves PL, Loukas A, Doolan DL.

Int J Mol Sci. 2018 Nov 6;19(11). pii: E3490. doi: 10.3390/ijms19113490.

2.

A balanced pro-inflammatory and regulatory cytokine signature in young African children is associated with lower risk of clinical malaria.

Dobaño C, Nhabomba AJ, Manaca MN, Berthoud T, Aguilar R, Quintó L, Barbosa A, Rodríguez MH, Jiménez A, Groves PL, Santano R, Bassat Q, Aponte JJ, Guinovart C, Doolan DL, Alonso PL.

Clin Infect Dis. 2018 Oct 31. doi: 10.1093/cid/ciy934. [Epub ahead of print]

PMID:
30380038
3.

ISV Congress back to Europe.

Doolan DL, Lu S.

Hum Vaccin Immunother. 2018;14(9):2101-2104. doi: 10.1080/21645515.2018.1518065. No abstract available.

PMID:
30285587
4.

Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection.

Lutzky VP, Ratnatunga CN, Smith DJ, Kupz A, Doolan DL, Reid DW, Thomson RM, Bell SC, Miles JJ.

Front Immunol. 2018 Jun 11;9:1319. doi: 10.3389/fimmu.2018.01319. eCollection 2018.

5.

High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection.

Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM, Aponte JJ, Ordi J, Doolan DL, Mayor A, Alonso PL.

Malar J. 2018 May 10;17(1):177. doi: 10.1186/s12936-018-2317-2.

6.

Influence of Physicochemical Properties of Lipopeptide Adjuvants on the Immune Response: A Rationale for Engineering a Potent Vaccine.

Eskandari S, Pattinson DJ, Stephenson RJ, Groves PL, Apte SH, Sedaghat B, Chandurudu S, Doolan DL, Toth I.

Chemistry. 2018 Jul 11;24(39):9892-9902. doi: 10.1002/chem.201801378. Epub 2018 Jun 19.

PMID:
29707835
7.

Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome.

Liu Z, Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Yu KJ, Lou PJ, Wang CP, Mulvenna J, Middeldorp JM, Bethony J, Chen CJ, Doolan DL, Hildesheim A.

J Infect Dis. 2018 May 25;217(12):1923-1931. doi: 10.1093/infdis/jiy122.

PMID:
29509907
8.

Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Teng A, Pablo J, Yu KJ PhD, Lou PJ MD, Wang CP, Liu Z, Chen CJ, Middeldorp J, Mulvenna J, Bethony J, Hildesheim A, Doolan DL.

Clin Cancer Res. 2018 Mar 15;24(6):1305-1314. doi: 10.1158/1078-0432.CCR-17-1929. Epub 2018 Jan 4.

PMID:
29301829
9.

Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses.

Schussek S, Trieu A, Apte SH, Sidney J, Sette A, Doolan DL.

Sci Rep. 2017 Nov 8;7(1):15053. doi: 10.1038/s41598-017-15354-0.

10.

Profiling the Targets of Protective CD8+ T Cell Responses to Infection.

Bruder JT, Chen P, Ekberg G, Smith EC, Lazarski CA, Myers BA, Bolton J, Sedegah M, Villasante E, Richie TL, King CR, Aguiar JC, Doolan DL, Brough DE.

Mol Ther Methods Clin Dev. 2017 Aug 18;7:20-31. doi: 10.1016/j.omtm.2017.08.003. eCollection 2017 Dec 15.

11.

Dichotomous miR expression and immune responses following primary blood-stage malaria.

Burel JG, Apte SH, Groves PL, Boyle MJ, Langer C, Beeson JG, McCarthy JS, Doolan DL.

JCI Insight. 2017 Aug 3;2(15). pii: 93434. doi: 10.1172/jci.insight.93434. [Epub ahead of print]

12.

Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation.

Loughland JR, Minigo G, Sarovich DS, Field M, Tipping PE, Montes de Oca M, Piera KA, Amante FH, Barber BE, Grigg MJ, William T, Good MF, Doolan DL, Engwerda CR, Anstey NM, McCarthy JS, Woodberry T.

Sci Rep. 2017 Jun 1;7(1):2596. doi: 10.1038/s41598-017-02096-2.

13.

Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation.

Woodberry T, Loughland JR, Minigo G, Burel JG, Amante FH, Piera KA, McNeil Y, Yeo TW, Good MF, Doolan DL, Engwerda CR, McCarthy JS, Anstey NM.

Infect Immun. 2017 May 23;85(6). pii: e00986-16. doi: 10.1128/IAI.00986-16. Print 2017 Jun.

14.

Polyfunctional and IFN-γ monofunctional human CD4+ T cell populations are molecularly distinct.

Burel JG, Apte SH, Groves PL, McCarthy JS, Doolan DL.

JCI Insight. 2017 Feb 9;2(3):e87499. doi: 10.1172/jci.insight.87499.

15.

A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.

Obaldia N 3rd, Stockelman MG, Otero W, Cockrill JA, Ganeshan H, Abot EN, Zhang J, Limbach K, Charoenvit Y, Doolan DL, Tang DC, Richie TL.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00539-16. doi: 10.1128/CVI.00539-16. Print 2017 Apr.

16.

Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential.

Burel JG, Apte SH, McCarthy JS, Doolan DL.

PLoS Negl Trop Dis. 2016 Dec 8;10(12):e0005031. doi: 10.1371/journal.pntd.0005031. eCollection 2016 Dec.

17.

Mining, visualizing and comparing multidimensional biomolecular data using the Genomics Data Miner (GMine) Web-Server.

Proietti C, Zakrzewski M, Watkins TS, Berger B, Hasan S, Ratnatunga CN, Brion MJ, Crompton PD, Miles JJ, Doolan DL, Krause L.

Sci Rep. 2016 Dec 6;6:38178. doi: 10.1038/srep38178.

18.

Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection.

Montes de Oca M, Kumar R, Rivera FL, Amante FH, Sheel M, Faleiro RJ, Bunn PT, Best SE, Beattie L, Ng SS, Edwards CL, Boyle GM, Price RN, Anstey NM, Loughland JR, Burel J, Doolan DL, Haque A, McCarthy JS, Engwerda CR.

Cell Rep. 2016 Oct 4;17(2):399-412. doi: 10.1016/j.celrep.2016.09.015.

19.

Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-γ Production.

Burel JG, Apte SH, Groves PL, Klein K, McCarthy JS, Doolan DL.

PLoS Pathog. 2016 Sep 23;12(9):e1005839. doi: 10.1371/journal.ppat.1005839. eCollection 2016 Sep.

20.

Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity.

Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, Luke TC, Charoenvit Y, Goh LM, Berzins MP, Bebris L, Sacci JB Jr, De La Vega P, Wang R, Ganeshan H, Abot EN, Carucci DJ, Doolan DL, Brice GT, Kumar A, Aguiar J, Nutman TB, Leitman SF, Hoffman SL, Epstein JE, Richie TL.

Malar J. 2016 Jul 22;15(1):377. doi: 10.1186/s12936-016-1435-y.

21.

Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection.

Raja AI, Cai Y, Reiman JM, Groves P, Chakravarty S, McPhun V, Doolan DL, Cockburn I, Hoffman SL, Stanisic DI, Good MF.

Infect Immun. 2016 Jul 21;84(8):2274-2288. doi: 10.1128/IAI.00157-16. Print 2016 Aug.

22.

Development of a cytokine-secreting-based assay for the identification, sorting and transcriptomic analysis of polyfunctional human T cells.

Burel JG, Apte SH, Doolan DL.

Eur Cytokine Netw. 2015 Oct-Dec;26(4):67-72. doi: 10.1684/ecn.2015.0369.

23.

Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection.

Loughland JR, Minigo G, Burel J, Tipping PE, Piera KA, Amante FH, Engwerda CR, Good MF, Doolan DL, Anstey NM, McCarthy JS, Woodberry T.

Infect Immun. 2016 Apr 22;84(5):1403-1412. doi: 10.1128/IAI.01522-15. Print 2016 May.

24.

Immunomics: a 21st century approach to vaccine development for complex pathogens.

De Sousa KP, Doolan DL.

Parasitology. 2016 Feb;143(2):236-44. doi: 10.1017/S0031182015001079. Review.

PMID:
26864136
25.

Defining the targets of antiparasitic compounds.

Skinner-Adams TS, Sumanadasa SD, Fisher GM, Davis RA, Doolan DL, Andrews KT.

Drug Discov Today. 2016 May;21(5):725-39. doi: 10.1016/j.drudis.2016.01.002. Epub 2016 Jan 16. Review.

PMID:
26784142
26.

Synthesis of Mannosylated Lipopeptides with Receptor Targeting Properties.

Sedaghat B, Stephenson RJ, Giddam AK, Eskandari S, Apte SH, Pattinson DJ, Doolan DL, Toth I.

Bioconjug Chem. 2016 Mar 16;27(3):533-48. doi: 10.1021/acs.bioconjchem.5b00547. Epub 2016 Jan 25.

PMID:
26735314
27.

Systems Approaches towards Molecular Profiling of Human Immunity.

Burel JG, Apte SH, Doolan DL.

Trends Immunol. 2016 Jan;37(1):53-67. doi: 10.1016/j.it.2015.11.006. Epub 2015 Dec 5. Review.

PMID:
26669258
28.

Systematic evaluation of self-adjuvanting lipopeptide nano-vaccine platforms for the induction of potent CD8(+) T-cell responses.

Apte SH, Stephenson RJ, Simerska P, Groves PL, Aljohani S, Eskandari S, Toth I, Doolan DL.

Nanomedicine (Lond). 2016 Jan;11(2):137-52. doi: 10.2217/nnm.15.184. Epub 2015 Dec 11.

PMID:
26653407
29.

Large screen approaches to identify novel malaria vaccine candidates.

Davies DH, Duffy P, Bodmer JL, Felgner PL, Doolan DL.

Vaccine. 2015 Dec 22;33(52):7496-505. doi: 10.1016/j.vaccine.2015.09.059. Epub 2015 Oct 1. Review.

30.

Antibody Signatures Reflect Different Disease Pathologies in Patients With Schistosomiasis Due to Schistosoma japonicum.

Driguez P, Li Y, Gaze S, Pearson MS, Nakajima R, Trieu A, Doolan DL, Felgner PL, Hou X, Cardoso FC, Jasinskas A, Gobert GN, Loukas A, McManus DP.

J Infect Dis. 2016 Jan 1;213(1):122-30. doi: 10.1093/infdis/jiv356. Epub 2015 Jul 6.

PMID:
26150545
31.

Specific humoral response of hosts with variable schistosomiasis susceptibility.

Driguez P, McWilliam HE, Gaze S, Piedrafita D, Pearson MS, Nakajima R, Duke M, Trieu A, Doolan DL, Cardoso FC, Jasinskas A, Gobert GN, Felgner PL, Loukas A, Meeusen E, McManus DP.

Immunol Cell Biol. 2016 Jan;94(1):52-65. doi: 10.1038/icb.2015.61. Epub 2015 Jun 5.

PMID:
26044065
32.

Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.

Pearson MS, Becker L, Driguez P, Young ND, Gaze S, Mendes T, Li XH, Doolan DL, Midzi N, Mduluza T, McManus DP, Wilson RA, Bethony JM, Nausch N, Mutapi F, Felgner PL, Loukas A.

Front Immunol. 2015 May 5;6:213. doi: 10.3389/fimmu.2015.00213. eCollection 2015.

33.

The case for a rational genome-based vaccine against malaria.

Proietti C, Doolan DL.

Front Microbiol. 2015 Jan 22;5:741. doi: 10.3389/fmicb.2014.00741. eCollection 2014. Review.

34.

Synthesis and characterisation of self-assembled and self-adjuvanting asymmetric multi-epitope lipopeptides of ovalbumin.

Eskandari S, Stephenson RJ, Fuaad AA, Apte SH, Doolan DL, Toth I.

Chemistry. 2015 Jan 12;21(3):1251-61. doi: 10.1002/chem.201404997. Epub 2014 Nov 14.

PMID:
25399845
35.

Protein microarrays for parasite antigen discovery.

Driguez P, Doolan DL, Molina DM, Loukas A, Trieu A, Felgner PL, McManus DP.

Methods Mol Biol. 2015;1201:221-33. doi: 10.1007/978-1-4939-1438-8_13.

PMID:
25388117
36.

Genome-based vaccine design: the promise for malaria and other infectious diseases.

Doolan DL, Apte SH, Proietti C.

Int J Parasitol. 2014 Oct 15;44(12):901-13. doi: 10.1016/j.ijpara.2014.07.010. Epub 2014 Sep 6. Review.

37.

Probing of a human proteome microarray with a recombinant pathogen protein reveals a novel mechanism by which hookworms suppress B-cell receptor signaling.

Tribolet L, Cantacessi C, Pickering DA, Navarro S, Doolan DL, Trieu A, Fei H, Chao Y, Hofmann A, Gasser RB, Giacomin PR, Loukas A.

J Infect Dis. 2015 Feb 1;211(3):416-25. doi: 10.1093/infdis/jiu451. Epub 2014 Aug 19.

PMID:
25139017
38.

An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas.

Gaze S, Driguez P, Pearson MS, Mendes T, Doolan DL, Trieu A, McManus DP, Gobert GN, Periago MV, Correa Oliveira R, Cardoso FC, Oliveira G, Nakajima R, Jasinskas A, Hung C, Liang L, Pablo J, Bethony JM, Felgner PL, Loukas A.

PLoS Pathog. 2014 Mar 27;10(3):e1004033. doi: 10.1371/journal.ppat.1004033. eCollection 2014 Mar.

39.

Genome- and proteome-wide screening strategies for antigen discovery and immunogen design.

Schussek S, Trieu A, Doolan DL.

Biotechnol Adv. 2014 Mar-Apr;32(2):403-14. doi: 10.1016/j.biotechadv.2013.12.006. Epub 2014 Jan 2. Review.

PMID:
24389084
40.

Highly sensitive quantitative real-time PCR for the detection of Plasmodium liver-stage parasite burden following low-dose sporozoite challenge.

Schussek S, Groves PL, Apte SH, Doolan DL.

PLoS One. 2013 Oct 2;8(10):e77811. doi: 10.1371/journal.pone.0077811. eCollection 2013.

41.

A novel candidate vaccine for cytauxzoonosis inferred from comparative apicomplexan genomics.

Tarigo JL, Scholl EH, McK Bird D, Brown CC, Cohn LA, Dean GA, Levy MG, Doolan DL, Trieu A, Nordone SK, Felgner PL, Vigil A, Birkenheuer AJ.

PLoS One. 2013 Aug 20;8(8):e71233. doi: 10.1371/journal.pone.0071233. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/943b121e-343b-4df1-a06b-7f8a205a057d.

42.

Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.

Schussek S, Trieu A, Apte SH, Sidney J, Sette A, Doolan DL.

Infect Immun. 2013 Oct;81(10):3586-99. doi: 10.1128/IAI.00544-13. Epub 2013 Jul 8.

43.

Subcutaneous cholera toxin exposure induces potent CD103⁺ dermal dendritic cell activation and migration.

Apte SH, Redmond AM, Groves PL, Schussek S, Pattinson DJ, Doolan DL.

Eur J Immunol. 2013 Oct;43(10):2707-17. doi: 10.1002/eji.201343475. Epub 2013 Sep 1.

44.

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).

Sedegah M, Kim Y, Ganeshan H, Huang J, Belmonte M, Abot E, Banania JG, Farooq F, McGrath S, Peters B, Sette A, Soisson L, Diggs C, Doolan DL, Tamminga C, Villasante E, Hollingdale MR, Richie TL.

Malar J. 2013 Jun 5;12:185. doi: 10.1186/1475-2875-12-185.

45.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14.

46.

Addressing the bottleneck at clinical testing of candidate malaria vaccines.

Doolan DL, Apte SH.

Pathog Glob Health. 2012 Oct;106(6):321-2. doi: 10.1179/2047772412Z.00000000081. No abstract available.

47.

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB Jr, Sedegah M, Nosek RA Jr, De La Vega P, Berzins MP, Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.

48.

Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model.

Apte SH, Groves PL, Skwarczynski M, Fujita Y, Chang C, Toth I, Doolan DL.

PLoS One. 2012;7(8):e40928. doi: 10.1371/journal.pone.0040928. Epub 2012 Aug 24.

49.

Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.

Bruder JT, Semenova E, Chen P, Limbach K, Patterson NB, Stefaniak ME, Konovalova S, Thomas C, Hamilton M, King CR, Richie TL, Doolan DL.

PLoS One. 2012;7(4):e33920. doi: 10.1371/journal.pone.0033920. Epub 2012 Apr 5. Erratum in: PLoS One. 2012;7(5): doi/10.1371/annotation/c110beed-3cac-48db-9039-ba4498d5db50.

50.

The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.

Guinovart C, Dobaño C, Bassat Q, Nhabomba A, Quintó L, Manaca MN, Aguilar R, Rodríguez MH, Barbosa A, Aponte JJ, Mayor AG, Renom M, Moraleda C, Roberts DJ, Schwarzer E, Le Souëf PN, Schofield L, Chitnis CE, Doolan DL, Alonso PL.

PLoS One. 2012;7(3):e32362. doi: 10.1371/journal.pone.0032362. Epub 2012 Mar 7.

Supplemental Content

Loading ...
Support Center